We report our early experience with distracting external fixation used to offload the hip after avascular necrosis (AVN) of the femoral head secondary to severe slipped upper femoral epiphysis (SUFE). A case series of five patients treated in a tertiary centre is reported. Electronic case records and radiographs were reviewed. Data recorded included demographics, initial presentation, timing of head collapse, timing and duration of distraction and outcome including referral to adult arthoplasty services. Mean age at presentation was 12 years (range 12–15). 4 were females. Initial treatment in 4 cases was a delayed cuneiform osteotomy and pinning, one patient underwent serendipitous reduction and percutaneous pinning. Mean duration to initial surgery was 10 days (range 5–16). All patients had femoral head collapse at a mean of 148 days from time of presentation. 2 patients required backing out of screws due to intra-articular protrusion. All patients underwent distraction at a mean 193 days from presentation. Average distraction achieved was 10 mm and duration of application was 125 days (range 91–139). All patients experienced improvement or resolution of pain but persistence of poor function, characterised by fixed adduction and limb length discrepancy. 3 patients were referred to adult arthroplasty services. This may be an effective treatment option for pain associated with AVN post SUFE. However, in our experience normal anatomy and function of the hip is not restored if performed after collapse of the femoral head. Consideration should be given to application of the distractor either at the time of initial fixation or prior to femoral head collapse. Authors believe that timing of the application of the distractor is critical for a successful outcome and recommend a prospective study with large numbers

Osteonecrosis is a pathologic bone condition caused by a disruption in the osseous circulation and impairment of normal cellular function which ultimately leads to bone infarction, osteocyte death, and joint degeneration. The incidence of osteonecrosis in the general population has been reported to be approximately 3 per 100,000 people. Up to 20,000 new cases are diagnosed each year and this condition is the indication for surgery in approximately 10% of all total hip arthroplasties performed in the United States. The hip is the most common joint affected, with approximately 75% of cases occurring in this joint, although multifocal osteonecrosis (defined as involvement of more than 3 joints) can also occur. Other commonly observed locations for osteonecrotic lesions include the knee, shoulder, wrist, and ankle. Joint preserving procedures may be performed for early stages without evidence of collapse, while intermediate lesions (e.g. femoral head collapse < 2 mm) may be candidates for joint preserving procedures such as bone grafting and rotational or proximal femoral varus osteotomies. However, total hip arthroplasty is usually required in advanced cases where there are large lesions, deformation of the femoral head, or acetabular involvement. Osteonecrosis has been traditionally associated with poor outcomes following total hip arthroplasty. However, recent studies using newer implant designs and surgical techniques have demonstrated outcomes comparable to the general total hip arthroplasty population. Johansson and colleagues, in a systematic reviewed of the literature, observed a decrease in the revision rate from 17% to 3% for arthroplasties performed later than 1990. The clinical outcomes were also comparable between patients who had osteoarthritis and those who had osteonecrosis. The young age at which these patients often present makes bearing surface choice challenging. Bearings that have low liner wear rates, such as ceramic bearings, had concerns with implant durability following reports of chipping and fracture of the ceramic. However, recent studies evaluating ceramic bearings in young patients with osteonecrosis have demonstrated that newer third and fourth generation ceramics have solved many of these issues. Byun et al. evaluated the clinical outcomes of ceramic bearings in patients younger than 30 years who had osteonecrosis and observed that at six year follow-up, none of the bearings had failed and that 95% of patients were able to continue with their prior occupation. Similar results at even longer follow-up periods were reported by Kim and colleagues who observed no failures in 93 ceramic hips at a mean follow-up of 11 years. Polyethylene wear continues to be a concern for these younger, more active patients. Early studies with non-highly cross linked polyethylene demonstrated high wear rates in these patients. Although newer polyethylene designs have become available which have demonstrated substantially lower wear than the traditional ultra high molecular weight polyethylene cups of the recent past, further studies are needed with these newer polyethylene bearings in the osteonecrosis population. The goal of treatment for femoral head osteonecrosis remains early diagnosis and joint preservation. For patients who present with femoral head collapse or acetabular involvement, total hip arthroplasty often is the only treatment option left. Although clinical outcomes for these patients were initially poor in earlier reports, the advent of modern cementless arthroplasty components, refined surgical techniques, and newer bearing designs have greatly improved the outcomes of this procedure

Osteonecrosis (ON) is a debilitating condition that can progress to severe arthritis of the hip. While its exact pathogenesis remains poorly understood, ON is known to be associated with risk factors such as corticosteroid use, alcoholism, and autoimmune disease. Initial radiographic evaluation can reveal sclerotic and cystic changes in the femoral head, which are usually the first clues in diagnosis. Despite these indicators, plain radiographs generally are not sufficient for diagnosis, therefore requiring subsequent magnetic resonance imaging (MRI) studies. Moreover, performing an appropriate assessment of these imaging modalities can help guide the course of treatment. Treatment options are aimed at slowing or stopping the onset of femoral head collapse and include non-operative management, joint preservation procedures, and total joint arthroplasty. Patients at risk of developing ON may benefit from early diagnosis because the characteristic small or medium-sized pre-collapse lesions that are associated with this stage can often be treated with a non-operative or joint preservation approach. However, patients typically present with advanced disease progression and sometimes an unsalvageable joint, thereby necessitating more invasive operative intervention. Surgical modalities include the use of osteotomy, core decompression, vascular grafts, bone graft substitutes, resurfacing, and finally, total hip arthroplasty. Additionally, reports from the past several decades describe improved outcomes and survivorship of these surgical treatment options. Therefore, our purpose is to highlight recent evidence regarding the management of ON with emphasis on the various forms of operative intervention as well as their outcomes

Introduction. Up to 60% of total hip arthroplasties (THA) in Asian populations arise from avascular necrosis (AVN), a bone disease that can lead to femoral head collapse. Current diagnostic methods to classify AVN have poor reproducibility and are not reliable in assessing the fracture risk. Femoral heads with an immediate fracture risk should be treated with a THA, conservative treatments are only successful in some cases and cause unnecessary patient suffering if used inappropriately. There is potential to improve the assessment of the fracture risk by using a combination of density-calibrated computed tomographic (QCT) imaging and engineering beam theory. The aim of this study was to validate the novel fracture prediction method against in-vitro compression tests on a series of six human femur specimens. Methods. Six femoral heads from six subjects were tested, a subset (n=3) included a hole drilled into the subchondral area of the femoral head via the femoral neck (University of Leeds, ethical approval MEEC13-002). The simulated lesions provided a method to validate the fracture prediction model with respect of AVN. The femoral heads were then modelled by a beam loaded with a single joint contact load. Material properties were assigned to the beam model from QCT-scans by using a density-modulus relationship. The maximum joint loading at which each bone cross-section was likely to fracture was calculated using a strain based failure criterion. Based on the predicted fracture loads, all six femoral heads (validation set) were classified into two groups, high fracture risk and low fracture risk (Figure 1). Beam theory did not allow for an accurate fracture load to be found because of the geometry of the femoral head. Therefore the predicted fracture loads of each of the six femoral heads was compared to the mean fracture load from twelve previously analysed human femoral heads (reference set) without lesions. The six cemented femurs were compression tested until failure. The subjects with a higher fracture risk were identified using both the experimental and beam tool outputs. Results. The computational tool correctly identified all femoral head samples which fractured at a significantly low load in-vitro (Figure 2). Both samples with a low experimental fracture load had an induced lesion in the subchondral area (Figure 3). Discussion. This study confirmed findings of a previous verification study on a disease models made from porcine femoral heads (Preutenborbeck et al. I-CORS2016). It demonstrated that fracture prediction based on beam theory is a viable tool to predict fracture. The tests confirmed that samples with a lesion in the weight bearing area were more likely to fracture at a low load however not all samples with a lesion fractured with a low load experimentally, indicating that a lesion alone is not a sufficient factor to predict fracture. The developed tool takes both structural and material properties into account when predicting the fracture risk. Therefore it might be superior to current diagnostic methods in this respect and it has the added advantage of being largely automated and therefore removing the majority of user bias. For any figures or tables, please contact the authors directly

Osteonecrosis of the femoral head (ONFH) is a debilitating, painful, progressive, and refractory disease that has multiple etiologic risk factors. It is caused by bone cell death, which itself has various causes, leading to femoral head collapse and subsequent osteoarthritis. ONFH primarily influences patients aged from 20 to 50 years; in addition, bilateral hip joints are involved in 75% of patients. Causes include use of corticosteroids, alcohol abuse, previous trauma, hemoglobinopathy, Gaucher disease, coagulopathies, and other diseases. No pharmacologic treatment has been shown to be effective for early ONFH. Outcomes of total hip arthroplasty (THA) for these young and active patients have some drawbacks, primarily due to the young age of these patients, limited lifetime and durability of the implants and their fixation, and the skeletal manifestations of osteonecrosis. As a result of these concerns, there has been an increased focus on early interventions for ONFH aimed at preservation of the native articulation. Core decompression is currently the most widely accepted surgical treatment at the early stage of avascular osteonecrosis (AVN); however, due to limited efficacy, its use has been debated. There is currently no standardised protocol for evaluating and treating osteonecrosis of the femoral head in adults in the United States. Although total hip replacement is the most frequent intervention for treatment of post-collapse (Steinberg stage-IIIB, IVB, V, and VI) osteonecrosis; core decompression is the most commonly offered intervention for symptomatic, pre-collapse (Steinberg stage-IB and IIB) osteonecrosis. Less frequently offered treatments include non-operative, pharmacologic or modality management, osteotomy, vascularised and non-vascularised bone-grafting, hemiarthroplasty, resurfacing and arthrodesis. A promising, minimally invasive, core decompression procedure combined with a mesenchymal stem cell grafting technique which restores vascularity and heals osteonecrotic lesions has become popularised. This procedure is called a bone marrow aspirate concentrate (BMAC) procedure. During a BMAC, mesenchymal stem cells (in the form of concentrated iliac crest bone marrow) are injected through a core decompression tract into the area of necrosis in the femoral head. Most patients with early (pre-collapse) disease have excellent results at 2 to 5 years of clinical follow-up. Patients are weight bearing as tolerated on crutches after the procedure for 6 weeks, and are able to go home on the same day or next day after surgery with minimal pain. We can report on the early, promising results of 300 patients with ONFH treated with BMAC in the United States by two expert hip surgeons with at least 75%-80% survivorship. The care of adults with osteonecrosis of the femoral head is highly variable. This paper will discuss the various non-operative and operative treatment algorithms for ONFH available today. We will also report on a promising, new technique (BMAC), which improves the efficacy of traditional core decompression for early ONFH. The goal of treatment of early ONFH is to avoid THA in young, active patients and this talk will discuss those interventions and treatments which help accomplish that goal

It has been reported that the total steroid dose and acute rejection episodes after organ transplantation is one of the risk factors for the development of osteonecrosis of the femoral head (ONFH), and ONFH in steroid-iduced subgroup may progress more aggressively to femoral head collapse requiring total hip arthroplasty. Despite inherent medical co-morbidities of solid organ transplantation patients, most authors recently have reported successful outcomes of THAs in those patients. But there are few comparative studies on the outcome of THAs for ONFH after different organ transplantations. The purpose of this study was to evaluate and compare a single tertiary referral institution's experience of performing primary THAs in kidney transplantation (KT) and liver transplantation (LT) patients with specific focus on the total steroid dose, clinical outcomes, and relationship between ONFH and absence or presence of acute rejection (AR). Between 1999 and 2010, 4,713 patients underwent organ transplantations (1,957 KT and 2,756 LT) and AR was occurred in 969 patients (20.6%) after transplantation. Among these patients, 131 patients (191 hips) underwent THA for ONFH, and they were retrospectively reviewed. In KT groups, there were 57 men and 36 women with a mean age of 43.7 years. In LT groups, there were 26 men and 13 women with a mean age of 50.4 years. We investigated the dose of steroid administration on both groups, the time period from transplantation to THA, Harris hips score (HHS), visual analogue scale (VAS) and complications. The mean follow up period was 8.1 years (range, 5 to 14 years). One-hundred and thirty-one (2.8%) patients [93 KT and 38 LT] underwent THA after transplantation. The total steroid dose after transplantations was significantly higher in KT group (10,420 mg) than that in LT group (4,567 mg), but the total steroid dose in the first 2 weeks after transplantation was significantly higher in LT group (3,478 mg) than that in KT group (2,564 mg). Twenty-three (2.4%) patients (19 KT and 4 LT) who underwent THA had an episode of AR. In LT group, the total steroid dose in AR groups was significantly higher than that in non-AR groups, whereas in KT group, there was no significant difference of the total steroid dose between AR group and non-AR group. The rate of THAs for ONFH was similar in both groups (2.4% in AR group, 2.9% in non-AR group). The mean time period from transplantation to THA was 986 days for KT and 1,649 days for LT patients. Both groups showed satisfactory HHS and VAS at final follow up, revealed no differences between the groups. The rate of THAs for ONFH was three times higher in KT patients than that in LT patients, but it was similar in both AR group and non-AR group. The total steroid dose was also higher in KT patients compared to LT patients. The clinical outcomes of THA were satisfactory with few complications in both KT and LT patients. Therefore, THAs seems to be a good option for the patients with symptomatic steroid-induced ONFH after KT and LT

Dysplasia has long been identified as a high-risk group for total hip replacement(THR). The underlying causes include younger age, underlying joint deformity, and greater tissue laxity. A higher failure rate has also been identified for hip resurfacing arthroplasty (HRA) in these patients. Many experts have advised avoiding HRA in these patients, although comparative studies are not available. We do not practice patient selection, because THR has not been proven any more reliable for these patients. Instead, we have taken the approach of studying the causes of failure and finding methods to improve the results of HRA in dysplasia patients. We have identified three primary failure modes for the young women who typically have dysplasia: failure of initial acetabular ingrowth (FAI), adverse wear related failure (AWRF), and early femoral failure (EFF: femoral neck fracture and head collapse). Improvements in technique to address all of these failure modes were in place by 2008: acetabular components with supplemental fixation for severe deformities (trispike), guidelines and intraoperative x-ray techniques to eliminate malpositioned acetabular components resulting in edge-loading, uncemented femoral fixation and a bone management protocol that has eliminated early femoral failure. Group I includes 142 cases done before 2008 and Group II includes 168 cases with minimum 2-year follow-up done after this date. Two-year failure rates improved from 5% (8/142) to 0.6% (1/168) and 5-year Kaplan-Meier survivorship improved from 93% to 99%. In Group II we have had only one failure (femoral neck fracture) in 168 dysplasia cases with 2–5 year follow-up. There have been no failures of acetabular ingrowth, no AWRF, no femoral head collapse, no failures of femoral ingrowth, no femoral loosenings, no dislocations and no nerve palsies. All acetabular components placed since 2008 meet our published RAIL (relative acetabular inclination limit) guidelines, which we have shown to be 99% reliable in avoiding high on levels and AWRF. Both groups were 70% female. With a mean bearing size 48mm (high-risk for HRA). There was also no differences in DEXA scan T score, BMI, ASA score, length of incision (4 inches) HHS, or patients participating in impact sports (UCLA activity score 9&10). In Group II the mean age was 3 years greater (52), the mean operative time was 20 minutes shorter (96 minutes), estimated blood loss was 120 ml less (140ml) and the mean hospital stay was one day shorter (2 days) probably reflective of greater experience in this single surgeon series. We have demonstrated that with sufficient surgeon experience and properly designed implants, hip resurfacing can be performed with a failure rate that is lower than most reports on THR for this disorder

Introduction. The results of the Birmingham Hip Resurfacing (BHR) device in several series reveal that the predominant mode of failure is femoral neck fracture or femoral head collapse and that careful patient selection and precise operative technique are vital to the success of this procedure. In this report we consider the results of BHR in patients with severe arthritis secondary to femoral head AVN. Methods. This was a single-surgeon consecutive series of BHRs with a minimum follow-up of 5 years. Fifty-nine patients with Ficat-Arlet grade III or IV femoral head AVN (66 hips) and treated with BHRs at a mean age of 43.9 years (range 19 to 67.7 years) were followed up for 5.4 to 9.6 years (mean 7.1 years). No patient died and none was lost to follow-up. Revision for any reason was the end-point and unrevised patients were assessed with Oxford hip scores. They were also reviewed clinically and with AP and lateral radiographs. Results. There were five failures in this cohort, giving a failure rate of 7.6% and a cumulative survivorship of 86% at 9.6 years. In one further patient the femoral component has tilted into varus from further collapse of the femoral head. He is asymptomatic but knows that he will need a revision if he develops symptoms. No other patient shows clinical or radiological adverse signs. Discussion. Several studies have shown that the results of arthroplasty are generally worse in AVN as compared to those in osteoarthritis. Reviewing the above results it appears to us that the relatively poorer cumulative survival observed in patients with a diagnosis of AVN (86%) compared to those with other diagnoses make AVN a relative contraindication to the hip resurfacing procedure

Management of symptomatic osteonecrosis of the hip includes either some type of head preservation procedure or a total hip arthroplasty (THA). In general, once there is collapse of the femoral head, femoral head preservation procedures have limited success. There are a number of different femoral head preservation procedures that are presently performed and there is no consensus regarding which one is most effective. These procedures involve a core decompression with some type of vascularised or nonvascularised grafting of the femoral head. Core decompression with bone grafting of the femoral head with stem cells harvested from the iliac crest and vascularised fibula grafts are the two most popular femoral head preservation procedures. Once the femoral head has collapsed then a THA should be performed when the patient has significant disability. In the past, total hip arthroplasty in osteonecrosis patients was not considered a highly successful procedure because it was performed in younger patients (most patients are younger than fifty years of age) and longevity was limited by wear and osteolysis. The advent of reliable cementless acetabular and femoral fixation and alternative bearing surfaces (i.e. highly crosslinked polyethylene liners) has been associated with improved outcomes and enhanced longevity. THA is considered the procedure of choice even for young patients (less than 30 years old) with collapse of the femoral head and significant pain and disability